

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 November 2007 (01.11.2007)

PCT

(10) International Publication Number
WO 2007/124319 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61K 31/496 (2006.01)
 C07D 233/90 (2006.01) A61K 31/382 (2006.01)
 C07D 405/12 (2006.01) A61K 31/41 (2006.01)
 C07D 405/14 (2006.01) A61K 31/4418 (2006.01)
 C07D 409/12 (2006.01) A61P 13/00 (2006.01)
 C07D 493/08 (2006.01) A61P 11/00 (2006.01)
 A61K 31/4178 (2006.01) A61P 35/00 (2006.01)
 A61K 31/5355 (2006.01)

Collegeville, Pennsylvania 19426 (US). **WALL, Mark** [CA/US]; 36 W. Mill Road, Flourtown, Pennsylvania 19031 (US). **WILSON, Kenneth** [US/US]; 119 Valley Place, Media, Pennsylvania 19063 (US).

(74) Agents: **JOHNSON, Philip S.** et al.; One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(21) International Application Number:

PCT/US2007/066868

(22) International Filing Date: 18 April 2007 (18.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/793,667 20 April 2006 (20.04.2006) US

(71) Applicant (for all designated States except US): **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ILLIG, Carl, R.** [US/US]; 25 Jonathan Drive, Phoenixville, Pennsylvania 19460 (US). **BALLENTINE, Shelley, K.** [US/US]; 1985 Armstrong Drive, Lansdale, Pennsylvania 19446 (US). **CHEN, Jinsheng** [CN/US]; 11 Fairwind Lane, Exton, Pennsylvania 19341 (US). **DESJARLAIS, Renee, Louise** [US/US]; 11 Cornwall Circle, Saint Davids, Pennsylvania 19087 (US). **MEEGALLA, Sanath, K.** [US/US]; 3822 Highland Drive, Boothwyn, Pennsylvania 19061 (US). **TOMCZUK, Bruce, E.** [US/US]; 333 Sonnet Lane,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF C-FMS KINASE



(I)

(57) Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R² and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.